Roi Altit1, William A Gray2. 1. Main Line Health, 100 E. Lancaster Ave, Wynnewood, PA, 19096, USA. 2. Main Line Health, 100 E. Lancaster Ave, Wynnewood, PA, 19096, USA. Grayw@mlhs.org.
Abstract
PURPOSE OF REVIEW: The purpose of this paper was to provide a review of the burden of peripheral arterial disease; to examine older therapies and their limitations; and especially to highlight new treatment innovations as well as the data supporting their use. RECENT FINDINGS: Building on the success of paclitaxel in the prevention of restenosis in the peripheral circulation, the newest generation drug-eluting stent is presented, which combines paclitaxel with a polymer-allowing the drug to be eluted slowly over 12 months. The positive results of the pilot MAJESTIC study led to the ongoing IMPERIAL trial. Limited data of bioresorbable scaffolds in above and below-the-knee applications are also reviewed. Endovascular therapy of peripheral arterial disease has had many advances in the preceding two decades. However, drug-eluting stent technology has had the greatest impact to date and holds great promise for the future.
PURPOSE OF REVIEW: The purpose of this paper was to provide a review of the burden of peripheral arterial disease; to examine older therapies and their limitations; and especially to highlight new treatment innovations as well as the data supporting their use. RECENT FINDINGS: Building on the success of paclitaxel in the prevention of restenosis in the peripheral circulation, the newest generation drug-eluting stent is presented, which combines paclitaxel with a polymer-allowing the drug to be eluted slowly over 12 months. The positive results of the pilot MAJESTIC study led to the ongoing IMPERIAL trial. Limited data of bioresorbable scaffolds in above and below-the-knee applications are also reviewed. Endovascular therapy of peripheral arterial disease has had many advances in the preceding two decades. However, drug-eluting stent technology has had the greatest impact to date and holds great promise for the future.
Authors: Marc Bosiers; Dierk Scheinert; Patrick Peeters; Giovanni Torsello; Thomas Zeller; Koen Deloose; Andrej Schmidt; Jörg Tessarek; Erwin Vinck; Lewis B Schwartz Journal: J Vasc Surg Date: 2011-12-14 Impact factor: 4.268
Authors: J I Weitz; J Byrne; G P Clagett; M E Farkouh; J M Porter; D L Sackett; D E Strandness; L M Taylor Journal: Circulation Date: 1996-12-01 Impact factor: 29.690
Authors: Aljoscha Rastan; Gunnar Tepe; Hans Krankenberg; Rainer Zahorsky; Ullrich Beschorner; Elias Noory; Sebastian Sixt; Thomas Schwarz; Klaus Brechtel; Catherine Böhme; Franz-Josef Neumann; Thomas Zeller Journal: Eur Heart J Date: 2011-05-26 Impact factor: 29.983
Authors: Stephan H Duda; Marc Bosiers; Johannes Lammer; Dierk Scheinert; Thomas Zeller; Vincent Oliva; Alexander Tielbeek; John Anderson; Benjamin Wiesinger; Gunnar Tepe; Alexandra Lansky; Michael R Jaff; Catharina Mudde; Hans Tielemans; Jean-Paul Beregi Journal: J Endovasc Ther Date: 2006-12 Impact factor: 3.487
Authors: Hans Krankenberg; Michael Schlüter; Hermann J Steinkamp; Karlheinz Bürgelin; Dierk Scheinert; Karl-Ludwig Schulte; Erich Minar; Patrick Peeters; Marc Bosiers; Gunnar Tepe; Bernhard Reimers; Felix Mahler; Thilo Tübler; Thomas Zeller Journal: Circulation Date: 2007-06-25 Impact factor: 29.690
Authors: Dierk Scheinert; Konstantinos Katsanos; Thomas Zeller; Renate Koppensteiner; Philip Commeau; Marc Bosiers; Hans Krankenberg; Iris Baumgartner; Dimitris Siablis; Johannes Lammer; Mariella Van Ransbeeck; Ayesha C Qureshi; Hans-Peter Stoll Journal: J Am Coll Cardiol Date: 2012-12-04 Impact factor: 24.094
Authors: Michael D Dake; Gary M Ansel; Michael R Jaff; Takao Ohki; Richard R Saxon; H Bob Smouse; Lindsay S Machan; Scott A Snyder; Erin E O'Leary; Anthony O Ragheb; Thomas Zeller Journal: Circulation Date: 2016-03-11 Impact factor: 29.690